Real-world Experience of Bezlotoxumab for Prevention of Clostridioides difficile Infection: A Retrospective Multicenter Cohort Study

BACKGROUND: Bezlotoxumab is approved for prevention of recurrence of Clostridioides difficile infection (CDI) in adults receiving standard of care (SoC) therapy based on findings from MODIFY clinical trials. However, utilization practices and validation of trial results in the real world are limited...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Open Forum Infect Dis
Autori principali: Hengel, Richard L, Ritter, Timothy E, Nathan, Ramesh V, Van Anglen, Lucinda J, Schroeder, Claudia P, Dillon, Ryan J, Marcella, Stephen W, Garey, Kevin W
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2020
Soggetti:
Major Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7186524/
https://ncbi.nlm.nih.gov/pubmed/32363211
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofaa097
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi